The morbidity and mortality of acute pulmonary embolism remain high despite advances in imaging techniques for rapid and accurate diagnosis. Treatment options are limited and directed toward anti-coagulation to prevent progression of an already-formed thrombus. Based on randomized controlled trials, the use of thrombolytics has been limited to a small patient population with cardiogenic shock and/or cardiopulmonary arrest.
展开▼
